Clare Herd

Clare Herd

Auto-generated profile, based on publicly available information

Clare Herd

Institute of Applied Health Research, University of Birmingham, Birmingham, UK

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2012 in BMJ
Verified
Journal Article
Open access
PDF file
CTClaire L Tomlinson
Claire L Tomlinson
SPSmitaa Patel
Smitaa Patel
CMCharmaine Meek
Charmaine Meek
CHClare P Herd
Clare P Herd
CCC. E. Clarke
C. E. Clarke
NINatalie Ives
Natalie Ives
Objective To assess the effectiveness of physiotherapy compared with no intervention in patients with Parkinson’s disease. Design Systematic review and meta-analysis of randomised controlled trials. Data sources Literature databases, trial registries, journals, abstract books, and conference proceedings, and reference lists, searched up to the end of January 2012. Review methods Randomised controlled trials comparing physiotherapy with no intervention in patients with Parkinson’s disease were eligible. Two authors independently abstracted data from each trial. Standard meta-analysis methods were used to assess the effectiveness of physiotherapy compared with no intervention. Tests for heterogeneity were used to assess for differences in treatment effect across different physiotherapy interventions used. Outcome measures were gait, functional mobility and balance, falls, clinician rated impairment and disability measures, patient rated quality of life, adverse events, compliance, and economic analysis outcomes. Results 39 trials of 1827 participants met the inclusion criteria, of which 29 trials provided data for the meta-analyses. Significant benefit from physiotherapy was reported for nine of 18 outcomes assessed. Outcomes which may be clinically significant were speed (0.04 m/s, 95% confidence interval 0.02 to 0.06, P<0.001), Berg balance scale (3.71 points, 2.30 to 5.11, P<0.001), and scores on the unified Parkinson’s disease rating scale (total score −6.15 points, −8.57 to −3.73, P<0.001; activities of daily living subscore −1.36, −2.41 to −0.30, P=0.01; motor subscore −5.01, −6.30 to −3.72, P<0.001). Indirect comparisons of the different physiotherapy interventions found no evidence that the treatment effect differed across the interventions for any outcomes assessed, apart from motor subscores on the unified Parkinson’s disease rating scale (in which one trial was found to be the cause of the heterogeneity). Conclusions Physiotherapy has short term benefits in Parkinson’s disease. A wide range of physiotherapy techniques are currently used to treat Parkinson’s disease, with little difference in treatment effects. Large, well designed, randomised controlled trials with improved methodology and reporting are needed to assess the efficacy and cost effectiveness of physiotherapy for treating Parkinson’s disease in the longer term.

10 September 2013 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
CTClaire L Tomlinson
Claire L Tomlinson
SPSmitaa Patel
Smitaa Patel
CMCharmaine Meek
Charmaine Meek
CHClare P Herd
Clare P Herd
CCCarl E Clarke
Carl E Clarke
NINatalie Ives
Natalie Ives

30 March 2020 in EP Europace
Verified
Journal Article
Open access
PDF file
JDJanine Dretzke
Janine Dretzke
NCNaomi Chuchu
Naomi Chuchu
RARidhi Agarwal
Ridhi Agarwal
CHClare Herd
Clare Herd
WCWinnie Chua
Winnie Chua
YTYemisi Takwoingi
Yemisi Takwoingi
Aims: We assessed the performance of modelsf (risk scores) for predicting recurrence of atrial fibrillation (AF) in patients who have undergone catheter ablation. Methods and results: Systematic searches of bibliographic databases were conducted (November 2018). Studies were eligible for inclusion if they reported the development, validation, or impact assessment of a model for predicting AF recurrence after ablation. Model performance (discrimination and calibration) measures were extracted. The Prediction Study Risk of Bias Assessment Tool (PROBAST) was used to assess risk of bias. Meta-analysis was not feasible due to clinical and methodological differences between studies, but c-statistics were presented in forest plots. Thirty-three studies developing or validating 13 models were included; eight studies compared two or more models. Common model variables were left atrial parameters, type of AF, and age. Model discriminatory ability was highly variable and no model had consistently poor or good performance. Most studies did not assess model calibration. The main risk of bias concern was the lack of internal validation which may have resulted in overly optimistic and/or biased model performance estimates. No model impact studies were identified. Conclusion: Our systematic review suggests that clinical risk prediction of AF after ablation has potential, but there remains a need for robust evaluation of risk factors and development of risk scores.

17 June 2014 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
CTClaire L Tomlinson
Claire L Tomlinson
CHClare P Herd
Clare P Herd
CCCarl E Clarke
Carl E Clarke
CMCharmaine Meek
Charmaine Meek
SPSmitaa Patel
Smitaa Patel
NINatalie Ives
Natalie Ives

16 July 2019 in BMJ Open
Verified
Journal Article
Open access
CHClare P Herd
Clare P Herd
CTClaire L Tomlinson
Claire L Tomlinson
CRCaroline Rick
Caroline Rick
WSWilliam J Scotton
William J Scotton
JEJulie Edwards
Julie Edwards
ASAj Sinclair
Aj Sinclair
Objectives: To assess the effects of botulinum toxin for prevention of migraine in adults. Design: Systematic review and meta-analysis. Data sources: CENTRAL, MEDLINE, Embase and trial registries. Eligibility criteria: We included randomised controlled trials (RCTs) of botulinum toxin compared with placebo, active treatment or clinically relevant different dose for adults with chronic or episodic migraine, with or without the additional diagnosis of medication overuse headache. Data extraction and synthesis: Cochrane methods were used to review double-blind RCTs. Twelve week post-treatment time-point data was analysed. Results: Twenty-eight trials (n=4190) were included. Trial quality was mixed. Botulinum toxin treatment resulted in reduced frequency of −2.0 migraine days/month (95% CI −2.8 to −1.1, n=1384) in chronic migraineurs compared with placebo. An improvement was seen in migraine severity, measured on a numerical rating scale 0 to 10 with 10 being maximal pain, of −2.70 cm (95% CI −3.31 to −2.09, n=75) and −4.9 cm (95% CI −6.56 to −3.24, n=32) for chronic and episodic migraine respectively. Botulinum toxin had a relative risk of treatment related adverse events twice that of placebo, but a reduced risk compared with active comparators (relative risk 0.76, 95% CI 0.59 to 0.98) and a low withdrawal rate (3%). Although individual trials reported non-inferiority to oral treatments, insufficient data were available for meta-analysis of effectiveness outcomes. Conclusions: In chronic migraine, botulinum toxin reduces migraine frequency by 2 days/month and has a favourable safety profile. Inclusion of medication overuse headache does not preclude its effectiveness. Evidence to support or refute efficacy in episodic migraine was not identified.

25 June 2018 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
CHClare P Herd
Clare P Herd
CTClaire L Tomlinson
Claire L Tomlinson
CRCaroline Rick
Caroline Rick
WSW J Scotton
W J Scotton
JEJulie Edwards
Julie Edwards
ASAlexandra Sinclair
Alexandra Sinclair